Antidiabetic Management Strategies for Treatment of Polycystic Ovarian Syndrome
Keywords:
Polycystic ovarian syndrome (PCOS), Insulin resistance, Antidiabetic drugs, Metformin, GLP-1 receptor agonists, DPP-4 inhibitors, Hormonal therapy, Oral contraceptives, Lifestyle interventions, Metabolic syndrome, Reproductive healthAbstract
Polycystic ovarian syndrome (PCOS) is a prevalent endocrine disorder characterized by metabolic and reproductive dysfunctions, with insulin resistance playing a central role. Antidiabetic drugs, particularly insulin sensitizers such as metformin, are essential in managing both metabolic and reproductive aspects of PCOS. This article explores the effectiveness of antidiabetic medications in PCOS management, focusing on metformin, GLP-1 receptor agonists, and DPP-4 inhibitors. The integration of these pharmacological agents with hormonal therapies, such as oral contraceptives, offers a comprehensive approach that targets both insulin resistance and hyperandrogenism. Additionally, the role of lifestyle interventions, including diet and exercise, is examined as a critical complement to pharmacotherapy. The article highlights the need for personalized treatment approaches and further research to optimize combination therapies for long-term outcomes. Ultimately, antidiabetic management strategies, when combined with hormonal and lifestyle modifications, represent a multifaceted approach to improving both metabolic and reproductive health in women with PCOS.
Downloads
Metrics
References
Yang S, Zhao L, He W, Mi Y. The effect of oral antidiabetic drugs on improving the endocrine and metabolic states in women with polycystic ovary syndrome: a systematic review and network meta-analysis. Drugs. 2022;82(14):1469-80.
Marinkovic-Radosevic J, Berkovic MC, Kruezi E, Bilic-Curcic I, Mrzljak A. Exploring new treatment options for polycystic ovary syndrome: review of a novel antidiabetic agent SGLT2 inhibitor. World journal of diabetes. 2021;12(7):932.
Helvaci N, Yildiz BO. Current and emerging drug treatment strategies for polycystic ovary syndrome. Expert Opinion on Pharmacotherapy. 2023;24(1):105-20.
Rashid R, Mir SA, Kareem O, Ali T, Ara R, Malik A, Amin F, Bader GN. Polycystic ovarian syndrome-current pharmacotherapy and clinical implications. Taiwanese Journal of Obstetrics and Gynecology. 2022;61(1):40-50.
Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. The Lancet. 2007;370(9588):685-97.
Franks S. Polycystic ovary syndrome. New England Journal of Medicine. 1995;333(13):853-61.
Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clinical endocrinology. 2004;60(1):1-7.
Catteau-Jonard S, Dewailly D. Pathophysiology of polycystic ovary syndrome: the role of hyperandrogenism. Polycystic ovary syndrome. 2013;40:22-7.
Guzick D. Polycystic ovary syndrome: symptomatology, pathophysiology, and epidemiology. American journal of obstetrics and gynecology. 1998;179(6):S89-93.
Matalliotakis I, Kourtis A, Koukoura O, Panidis D. Polycystic ovary syndrome: etiology and pathogenesis. Archives of gynecology and obstetrics. 2006;274:187-97.
Weiss JM, Tauchert S, Ludwig AK, Diedrich K. Treatment strategies in PCOS patients. Reproductive biomedicine online. 2005;10:67-74.
Mauvais-Jarvis P, Bricaire C. Pathophysiology of polycystic ovary syndrome. Journal of Steroid Biochemistry. 1989;33(4):791-4.
Spritzer PM, Motta AB, Petermann T, Diamanti Kandarakis E. Novel strategies in the management of polycystic ovary syndrome.
Shamis M. Management of Insulin Resistance in Polycystic Ovary Syndrome (Master's thesis, Lithuanian University of Health Sciences (Lithuania)).
Panidis D, Tziomalos K, Papadakis E, Vosnakis C, Chatzis P, Katsikis I. Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility. Endocrine. 2013;44:583-90.
Sheehan MT. Polycystic ovarian syndrome: diagnosis and management. Clinical Medicine & Research. 2004;2(1):13-27.
Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism. 1990;39(2):167-74.
Poretsky L, Grigorescu F, Seibel M, Moses AC, Flier JS. Distribution and characterization of insulin and insulin-like growth factor I receptors in normal human ovary. The Journal of Clinical Endocrinology & Metabolism. 1985;61(4):728-34.
PRELEVIC GM, WURZBURGER MI, BALINT-PERIC UI, NESIC JS. Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndrome. Obstetrical & Gynecological Survey. 1991;46(8):570-1.
Bridger T, MacDonald S, Baltzer F, Rodd C. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Archives of pediatrics & adolescent medicine. 2006;160(3):241-6.
Løvvik TS, Carlsen SM, Salvesen Ø, Steffensen B, Bixo M, Gómez-Real F, Lønnebotn M, Hestvold KV, Zabielska R, Hirschberg AL, Trouva A. Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. The lancet Diabetes & endocrinology. 2019;7(4):256-66.
El Maghraby HA, Nafee T, Guiziry D, Elnashar A. Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24 month follow up period. Middle East Fertility Society Journal. 2015;20(3):131-7.
Froment P, Touraine P. Thiazolidinediones and fertility in polycystic ovary syndrome (PCOS). PPAR research. 2006;(1):073986.
Du Q, Yang S, Wang YJ, Wu B, Zhao YY, Fan B. Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials. Adv Ther. 2012;29(9):763-74. doi: 10.1007/s12325-012-0044-6. Epub 2012 Aug 28. PMID: 22932791.
Seto-Young D, Paliou M, Schlosser J, Avtanski D, Park A, Patel P, Holcomb K, Chang P, Poretsky L. Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. The Journal of Clinical Endocrinology & Metabolism. 2005;90(11):6099-105.
Greff D, Juhász AE, Váncsa S, Váradi A, Sipos Z, Szinte J, Park S, Hegyi P, Nyirády P, Ács N, Várbíró S, Horváth EM. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2023;21(1):10. doi: 10.1186/s12958-023-01055-z. PMID: 36703143; PMCID: PMC9878965.
Unfer V, Facchinetti F, Orrù B, Giordani B, Nestler J. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocrine Connections. 2017;6(8):647-58.
Fitz V, Graca S, Mahalingaiah S, Liu J, Lai L, Butt A, Armour M, Rao V, Naidoo D, Maunder A, Yang G. Inositol for Polycystic Ovary Syndrome: a systematic review and meta-analysis to inform the 2023 update of the International Evidence-Based PCOS Guidelines. The Journal of Clinical Endocrinology & Metabolism. 2024;109(6):1630-55.
Han Y, Li Y, He B. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reproductive biomedicine online. 2019;39(2):332-42.
Lamos EM, Malek R, Davis SN. GLP-1 receptor agonists in the treatment of polycystic ovary syndrome. Expert Review of Clinical Pharmacology. 2017;10(4):401-8.
Cena H, Chiovato L, Nappi RE. Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists. The Journal of Clinical Endocrinology & Metabolism. 2020;105(8):e2695-709.
Lempesis IG, Apple SJ, Duarte G, Palaiodimos L, Kalaitzopoulos DR, Dalamaga M, Kokkinidis DG. Cardiometabolic effects of SGLT2 inhibitors on polycystic ovary syndrome. Diabetes/Metabolism Research and Reviews. 2023;39(6):e3682.
Rakic D, Jakovljevic V, Jovic N, Bicanin Ilic M, Dimitrijevic A, Vulovic T, Arsenijevic P, Sretenovic J, Nikolic M, Petrovich Fisenko V, Bolevich S. The potential of SGLT-2 inhibitors in the treatment of polycystic ovary syndrome: the current status and future perspectives. Biomedicines. 2023;11(4):998.
Tzotzas T, N Karras S, Katsiki N. Glucagon-like peptide-1 (GLP-1) receptor agonists in the treatment of obese women with polycystic ovary syndrome. Current vascular pharmacology. 2017;15(3):218-29.
Ferjan S, Janez A, Jensterle M. DPP4 inhibitor sitagliptin as a potential treatment option in metformin-intolerant obese women with polycystic ovary syndrome: a pilot randomized study. Endocrine Practice. 2018;24(1):69-77.
Jensterle M, Goricar K, Janez A. Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. Endocrine Research. 2017;42(4):261-8.
Ferjan S, Janez A, Jensterle M. Dipeptidyl peptidase-4 inhibitor sitagliptin prevented weight regain in obese women with polycystic ovary syndrome previously treated with liraglutide: a pilot randomized study. Metabolic syndrome and related disorders. 2017;15(10):515-20.
Velazquez C, Herrero Y, Bianchi MS, Cohen DJ, Cuasnicu P, Prost K, Marinoni R, Pascuali N, Parborell F, Abramovich D. Beneficial effects of metformin on mice female fertility after a high-fat diet intake. Molecular and Cellular Endocrinology. 2023;575:111995.
Genazzani AD, Santagni S, Rattighieri E, Chierchia E, Despini G, Prati A, Ricchieri F. PCOS and insulin resistance (IR): from lifestyle to insulin sensitizers. Frontiers in Gynecological Endocrinology: Volume 2: From Basic Science to Clinical Application. 2015:11-23.
Biswas S. A review on the pharmacological effects of hormonal and antidiabetic drugs in the treatment of Polycystic Ovary Syndrome (Doctoral dissertation, Brac University).
Moran A, Jacobs Jr DR, Steinberger J, Steffen LM, Pankow JS, Hong CP, Sinaiko AR. Changes in insulin resistance and cardiovascular risk during adolescence: establishment of differential risk in males and females. Circulation. 2008;117(18):2361-8.
Jensterle M, Janez A, Fliers E, DeVries JH, Vrtacnik-Bokal E, Siegelaar SE. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Human reproduction update. 2019;25(4):504-17.
Wei W, Zhao H, Wang A, Sui M, Liang K, Deng H, Ma Y, Zhang Y, Zhang H, Guan Y. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European journal of endocrinology. 2012;166(1):99-105.
Elkind-Hirsch KE, Chappell N, Shaler D, Storment J, Bellanger D. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertility and sterility. 2022;118(2):371-81.
Palomba S, Falbo A, La Sala GB. Metformin and gonadotropins for ovulation induction in patients with polycystic ovary syndrome: a systematic review with meta-analysis of randomized controlled trials. Reproductive biology and endocrinology. 2014;12:1-5.
Belli SH, Graffigna MN, Oneto A, Otero P, Schurman L, Levalle OA. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertility and Sterility. 2004;81(3):624-9.
Ibanez L, López-Bermejo A, Díaz M, Marcos MV, de Zegher F. Early metformin therapy (age 8–12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. The Journal of Clinical Endocrinology & Metabolism. 2011;96(8):E1262-7.
Basciani S, Nordio M, Dinicola S, Unfer V, Gnessi L. Diet plus inositols, α-lactalbumin and Gymnema sylvestre: the successful combo to restore body weight and metabolic profile in obese and dysmetabolic patients. Nutrients. 2023;15(14):3142.
Tiwari G, Tiwari R, Kaur A. Pharmaceutical Considerations of Translabial Formulations for Treatment of Parkinson's Disease: A Concept of Drug Delivery for Unconscious Patients. Curr Drug Deliv. 2023;20(8):1163-1175.
Ramachandran V, V IK, Hr KK, Tiwari R, Tiwari G. Biochanin-A: A Bioactive Natural Product with Versatile Therapeutic Perspectives. Curr Drug Res Rev. 2022;14(3):225-238.
Tiwari R, Tiwari G, Sharma S, Ramachandran V. An Exploration of Herbal Extracts Loaded Phyto-phospholipid Complexes (Phytosomes) Against Polycystic Ovarian Syndrome: Formulation Considerations. Pharm Nanotechnol. 2023;11(1):44-55.
Sethi P, C RD, Borra R, Vahora S, Vashi A, Mukherjee RK, Pavani B, Tiwari G. Mechanistic Insights into Tau Protein-Mediated Regulation of Oxidative Stress. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024;40:e20240028.
Yadav K, Tiwari G, Shivhare B, Tiwari R, Vijapur LS. Development and Evaluation of Herbal-Enriched Nutraceutical Gummies for Pediatric Health. Pharmacog Res. 2024;16(4):872-8.
Tiwari R, Khatri C, Tyagi LK, Tiwari G. Expanded Therapeutic Applications of Holarrhena Antidysenterica: A Review. Comb Chem High Throughput Screen. 2024;27(9):1257-1275.
Tiwari G, Patil A, Sethi P, Agrawal A, Ansari VA, Posa MK, Aher VD. Design, optimization, and evaluation of methotrexate loaded and albumin coated polymeric nanoparticles. J Biomater Sci Polym Ed. 2024;35(13):2068-2089.
Tiwari G, Shukla A, Singh A, Tiwari R. Computer Simulation for Effective Pharmaceutical Kinetics and Dynamics: A Review. Curr Comput Aided Drug Des. 2024;20(4):325-340.
Patil A, Singh G, Dighe RD, Dev D, Patel BA, Rudrangi S, Tiwari G. Preparation, optimization, and evaluation of ligand-tethered atovaquone-proguanil-loaded nanoparticles for malaria treatment. J Biomater Sci Polym Ed. 2024;1-32.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.